Keyword: Braeburn Pharmaceuticals
Titan gets the OK to start stage two in a trial of its ropinirole implant for Parkinson’s—but has to postpone because of financial constraints.
Titan Pharmaceuticals and Braeburn are parting ways over a licensing deal they inked back in 2012 for commercial rights to distribute Probuphine, a small implanted device about the size of a matchstick that dispenses a low-level dose of buprenorphine over six months.
Mebias presented rat data showing its mu opioid drugs could become a weapon in the scramble to combat the opioid epidemic.
Tocagen has filed to raise up to $86 million in an IPO to take its brain cancer gene therapy combination through the first part of a phase 2/3 trial.
Braeburn Pharmaceuticals has filed for a $150 million IPO to fund commercialization of its six-month opioid addiction implant.